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ABSTRACT
The present study reports the developmental patterns of expres-
sion of adrenomedullin (AM) in rat andmouse embryos. AM is a novel
multifunctional peptide recently isolated from a human pheochro-
mocytoma, which has been shown to promote growth in a variety of
mammalian cell lines. We have applied several techniques to inves-
tigate the localization of both the AM peptide and its receptor
throughout development. Immunocytochemical detection has been
performedusing different specific antibodies againstAMand its gene-
related peptide pro-AM N-terminal 20 peptide. In situ hybridization
showed the localization of the messenger RNAs for AM and its re-
ceptor. Western blot analysis together with reverse transcription-
PCR gave further support to the localization of AM and its receptor
in a variety of embryonic tissues. The localization of the receptor
paralleled that of AM itself, suggesting an autocrine or paracrine
mode of action. The spatio-temporal pattern of expression of AM in
cardiovascular, neural, and skeletal-forming tissues as well as in the
main embryonic internal organs is described. The primitive placenta,
especially the giant trophoblastic cells, shows high levels of AM and
AM receptor. The heart is the first organ that expresses AM during
development. The kidney, lung, and developing tooth, in which epi-
thelial-mesenchymal interactions are taking place, show specific pat-
terns of AM expression. In several regions of the embryo, the patterns
of AM expression correspond to the degree of differentiation. The
possible involvement of AM in the control of embryonic invasion,
proliferation, and differentiation is discussed. (Endocrinology 138:
440–451, 1997)
ADRENOMEDULLIN (AM) is a multifunctional peptidethat has been identified from extracts of human pheo-
chromocytoma (18). It is comprised of 52 amino acids and
shows slight structural homology with calcitonin gene-re-
lated peptide (CGRP). Initial characterization demonstrated
AM as a potent mediator of hypotension when injected iv
into rats (18). AM and its gene-related peptide, proad-
renomedullin N-terminal 20 peptide (PAMP), are the two
known bioactive amidated peptides generated by posttrans-
lational enzymatic processing of the 185-amino acid pre-
pro-AM molecule (19). AM elevates intracellular cAMP lev-
els in several cell types, and a receptor for AM (AM-R) has
recently been cloned and sequenced (16). PAMP has no se-
quence homology with AM or CGRP and seems to act via a
different receptor system (30). The expression of AM has
been shown in a variety of adult rat, human, and porcine
tissues, including heart, adrenals, brain, kidney, pancreas,
aorta, lung, and brain- and lung-derived tumors (10, 23, 24,
31).
Apart from the vasorelaxant effect, several other functions
have been reported for this peptide hormone. AM has been
implicated in the regulation of renal function by means of its
potent natriuretic and diuretic properties (14), has bron-
chodilatory effects (15), and inhibits the release of aldoste-
rone, ACTH, and insulin (24, 28). Recent data suggest the
involvement of AM in the regulation of growth. AM stim-
ulates DNA synthesis and cell proliferation of Swiss 3T3
fibroblasts acting via the elevation of intracellular cAMP (32).
Low concentrations (10–100 nm) of AM induced the cell cycle
progression from G0 to G1 phase and the expression of c-fos
messenger RNA (mRNA) in cultured rat aorta muscle cells
(20). Moreover, our recent data show that numerous malig-
nant cell lines express not only AM mRNA but also the
mRNA for its receptor (25), suggesting the existence of an
autocrine or paracrine type of growth regulation in human
tumors. We also demonstrated that an inactivating anti-AM
monoclonal antibody inhibits tumor cell growth in a dose-
dependent manner, an effect that could be reversed by ex-
ogenous AM (25). Consistent with this proposed involve-
ment in tumor growth control, AM has been found to be
expressed in a variety of human malignancies of both neural
and pulmonary lineage (23, 29).
An increasing number of peptides have been shown to be
implicated in the long term modulation of growth and dif-
ferentiation, not only in normal tissues but also in cancer,
wound repair, and embryogenesis (3, 22, 26). These obser-
vations together with the recent data linking AM to the
control of normal and tumor cells prompted us to investigate
the possible role of AM in embryogenesis. Although the
localization of AM in adult mammalian tissues and human
neoplasms has been the object of some studies, the expres-
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sion pattern during embryogenesis has not been reported. To
gain further insight into the role of AM in embryonic de-
velopment, we analyzed its expression in the mouse [em-
bryonic days 8–16 (E8-16)] and the rat (E10-18) embryo. In
the present studywe show the expression of AM, AM-R, and
PAMP during rodent embryogenesis bymeans of molecular,
biochemical, and histochemical techniques.
Materials and Methods
Animals and tissue samples
Sections of Sprague-Dawley rat and NIH Swiss mouse staged em-
bryos (Novagene, Madison, WI) were used. Adult female animals were
caged with adult males overnight. The presence of a vaginal plug the
following morning was designated day 0 of pregnancy. All specimens
were fixed for 24 h in 4% buffered paraformaldehyde, embedded in
paraffin, and sectioned at 7-mm thickness. Sections were mounted onto
slides treated with Vectabond (Vector Laboratories, Burlingame, CA).
For protein and mRNA extraction, pregnant rats (16 and 18 days after
the morning when a vaginal plug was found) were used. Dams were
obtained from SAIC (Frederick, MD; protocol 95/125) and killed by CO2
overdose. The uterus was quickly removed and kept at 4 C while each
embryo was dissected. Samples were kept at 280 C until extracted.
Antibodies
A previously reported, well characterized rabbit antiserum (no. 2343)
was used to localizeAM immunoreactivity in embryonic tissues (23). For
the localization of PAMP, an antibody (no. 2463) was raised in rabbits
against a synthetic peptide (P070) that represents the C-terminal eight
amino acids of PAMP linked to a YY residue (YYWNKWALSR-NH2).
The P070 peptide was C-terminally amidated to conform with the C-
terminus of native PAMP. The peptide was linked to key limpet he-
mocyanin via glutaraldehyde cross-linkage before immunization of the
rabbits. The antibody was characterized for binding specificity using a
solid phase RIAwith [125I]proteinA as the detector. In brief, test peptides
were passively absorbed onto individual wells (100 ng/well; overnight
at 4 C) of a 96-well polyvinylchloride microtiter plate (Dynatech Lab-
oratories, Chantilly, VA), after which the plate was coated with 1% BSA
in PBS to minimize nonspecific binding. Test peptides included PAMP,
P070, AM, CGRP, gastrin-releasing peptide, glucagon-like peptide-1,
vasoactive intestinal peptide, IBE1, IBE2, substance P, arginine vaso-
pressin, GRF, cholecystokinin, amylin, gastrin, oxytocin, calcitonin,
aMSH, pancreatic polypeptide, peptide tyrosine-tyrosine, and Tabanus
atratus hypotrehalosemic hormone (Peninsula Laboratories, Belmont,
CA); BSA (Sigma Chemical Co., St. Louis, MO) was used as a negative
control. Most of these test peptides were chosen because they are also
C-terminally amidated. The antibodywas tested at serial 2-fold dilutions
ranging from 1:100 to 1:204,800. Very slight cross-reactivity was ob-
served with glucagon-like peptide-1 and IBE2, and this was completely
abolished when the antibody was preabsorbed with the peptide at 1
nmol/ml. The rest of the peptides tested gave negative results, except
for PAMP and P070, which in our assay were readily recognized by the
polyclonal antibody diluted up to 1:25,600.
Immunocytochemical technique
For the immunocytochemical localization of AM and PAMP in par-
affin sections, the avidin-biotin complex technique was employed. Op-
timal dilution for anti-P072 was 1:1000, whereas the anti-P070 was used
at a 1:600 dilution. After overnight treatment with the primary anti-
serum, sections were incubated with biotinylated goat antirabbit anti-
serum (Vector Laboratories) diluted 1:200. The sections were then
treated with the avidin-biotin peroxidase complex (Vector Laboratories)
diluted 1:100 in PBS. Peroxidase activity was demonstrated using dia-
minobenzidine-H2O2 as substrate. Finally, the sections were lightly
counterstained with Gills’ hematoxylin.
Solid phase absorption controls were carried out by preincubation
(overnight at 4 C) of the primary antiserum with the equivalent peptide
previously adsorbed to the wall of a polystyrene tube at a concentration
of 10 mg/ml. Another negative control included the use of nonimmune
swine serum as first layer and gave no immunocytochemical reaction.
Reverse transcription-PCR (RT-PCR)
The oligonucleotide primers were synthesized using a MilliGen/
Biosearch 8700 DNA synthesizer (Millipore, Marlborough, MA). Primer
sets for AM detection were as follows: sense (AM 250–270), 59-AAG-
AAG-TGG-AAT-AAG-TGG-GCT-39; antisense (AM 523–542), 59-TGT-
GAA-CTG-GTA-GAT-CTG-GT-39; and nested probe antisense (AM
430–450), 59-TCT-GGC-GGT-AGC-GCT-TGA-CTC-39, with a predicted
product of 293 bp. For human AM-R amplification, the following rat
primers were selected from the published sequence (16): sense, AM-R-
(476–497), 59-AGC-GCC-ACC-AGC-ACC-GAA-TAC-G-39; antisense,
AM-R-(923–946), 59-AGA-GGA-TGG-GGT-TGG-CGA-CAC-AGT-39;
and antisense probe, AM-R788-811, 59-GGT-AGG-GCA-GCC-AGC-
AGA-TGA-CAA-39, yielding a 471-bp product. Procedures for RT-PCR
using these primers have been described previously (24). A Perkin-
Elmer 9600 Thermocycler (Norwalk, CT) was used to amplify the sam-
ples for 35 cycles, with annealing temperatures of 55 and 60 C, respec-
tively, for the ligand and its receptor. AM full-length probe was also
generated by the PCR technique from normal human lung complemen-
tary DNA (cDNA; Clontech, Palo Alto, CA). PCR was performed using
sense primer AM-(25–45) (59-CCA-CTT-CGG-GCT-TCT-CAC-TGC-39)
and antisense primer AM-(1304–1327) (59-CAC-GCG-AAC-AAC-TTT-
ACA-CCT-39) to obtain a 1303-bp product. Unique conditionswere used
during the PCR, with a (NH4)2SO4-based buffer [10 mm (NH4)2SO4, 10
mmKCl, 10 mm Tris-HCl (pH 8.4), 0.01% gelatin, and 0.1% Triton X-100]
containing 3.75 mmMgCl2. The annealing temperature was 55 C, and 35
cycleswere performed. The PCR productwas then cloned into the pCRII
vector (Invitrogen, San Diego, CA) following the manufacturer’s
procedures.
In situ hybridization
Detection of the mRNA of both AM and its membrane receptor
protein was performed using in situ hybridization. The full-length
cDNAs for AM and AM-R (16) were ligated into the expression vectors
pCRII and pcDNA1, respectively, and used to generate riboprobes. Both
plasmids were linearizedwith EcoRV and BamHI and used as a template
to synthesize digoxigenin-labeled sense and antisense RNA transcripts.
Hybridization was performed in a moist chamber at 46 C for 20 h in a
20-ml volume containing the probe. After stringency washes, visualiza-
tion of digoxigenin was performed using digoxigenin detection kit
(Boehringer Mannheim, Indianapolis, IN). Sense probes were used as
controls.
Western blotting
To extract the proteins, the tissue samples were immersed in 2 3
tricine sample buffer (with 8% SDS; Novex, San Diego, CA) containing
a 1-mm final concentration of each of the following protease inhibitors:
Pefabloc (Centerchem, Stamford, CT) and bestatin and phosphoramidon
(Sigma Chemical Co.). The tissuewas then homogenized, sonicated, and
clarified by ultracentrifugation, and the final protein concentration was
determined (BCA kit, Bio-Rad Laboratories, Richmond, CA). Tissue
extracts were diluted to an approximate protein concentration of 35
mg/50 ml, heated to 95 C for 3 min, and loaded into the sample well.
Tissue extracts were electrophoretically separated on a gradient 10–
20% tricine, SDS-PAGE gel (Novex) and run at 100 V for 2 h under
reducing (5% b-mercaptoethanol) conditions. Five nanograms of syn-
thetic AM were added to a separate well as a positive control. Transfer
blotting was accomplished in the same apparatus equipped with a
titanium plate electrode and transferred to a polyvinylidene difluoride
membrane (Immobilon PVDF, Millipore) at 30 V for 3 h. The membrane
was blocked overnight in 1% BSA-PBS, incubated for 1 h in a 1:1000
dilution of rabbit anti-AM (bleed 2343), washed three times in PBS,
exposed to 13 106 cpm [125I]proteinA for 30min at 4 C,washed six times
in PBS, dried, and autoradiographed overnight at280C onKodakXAR5
film (Eastman Kodak, Rochester, NY). The specificity control consisted
of a duplicate membrane incubated in antigen-preabsorbed (10 nmol/
ml) antiserum.
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Results
Widespread expression of AM was identified throughout
the embryonic development period of both mouse and rat.
The brown immunocytochemical signal for both AM and
PAMP and its intensity were modulated in a temporal fash-
ion during embryogenesis. With the exception of the ex-
traembryonic structures, low levels of AM and PAMP im-
munoreactivitywere detected in the embryo at the beginning
of organogenesis (mouse, E8-9; rat, E10-11), whereas these
levelswere dramatically increased during late organogenetic
and early fetal growth periods (mouse, E13-16; rat, E15-17;
Fig. 1, A–D). Table 1 summarizes the immunocytochemical
detection of AM in the organogenetic period of the mouse.
The distribution of AM- and PAMP-like immunoreactivities
in the different tissues throughout the multiple stages of
development of the two species studied were parallel; AM-
like immunoreactivity was generally stronger than PAMP-
like immunoreactivity (Fig. 1, D and E). The distribution for
AM mRNA was coincident with the results obtained by
immunocytochemical techniques. We also detected the
mRNA of the AM-R protein in several tissues of the murine
embryo at various stages.
RT-PCR was used to evaluate AM ligand and receptor
mRNA in a variety of rat embryonic (E16 and E18) tissues
(Fig. 2, A and B). The resulting 293- and 471-bp RT-PCR
products for AM and AM-R mRNA were confirmed by
Southern blottingwith antisense nested probes. Themajority
of fetal tissues tested were shown to express AM and AM-R
mRNA by RT-PCR, including the whole embryo, placenta,
yolk sac, heart, lung, liver, brain, and gut. Tissue extracts
from the same organs were examined for AM immunoreac-
tivity by Western blot analysis using a previously charac-
terized rabbit antiserum (23). Figure 2C illustrates the elec-
trophoretic profile of the AM-like peptides identified.
Molecular mass species of 18, 14, and 6 kDa were identified
in tissue lysates and presumably represent AM precursor,
processed intermediates, and the authentic peptide, respec-
tively. The specificity of our immune detection assay was
confirmed by an antibody absorption control that eliminated
the specific bands.
Expression of AM in mouse development
Placenta and yolk sac. In the E8 embryo, a prominent immu-
nocytochemical reaction was present in the primitive pla-
FIG. 1. Immunolocalization of AM and PAMP in early and late stages of mouse and rat development. AM and PAMP proteins were detected
as described inMaterials and Methods. A, Mouse E9. Primitive placenta and embryo immunostained for AM. B, Mouse E9. Primitive placenta
and embryo immunostained for PAMP. C, Rat E11. Placenta and embryo immunostained for AM. D, Mouse E16. Section of the whole embryo
immunostained for AM. E, Mouse E16. Section of the whole embryo immunostained for PAMP. F, Rat E16. Section of the whole embryo
immunostained for AM. Note that placental tissues are positively stained in A, B, and C. Magnification: A, B, and C, 310; D and E, 35; F, 36.
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centa, whereas very low immunoreactive signal was found
in the developing embryonic tissues (Fig. 1A and 3, A–C).
Maternal decidual cells and the embryonic cells of the ecto-
placental conewere intensely stained; the trophoblastic giant
cells were particularly distinct (Fig. 3B) The cells of the cho-
rionic plate were also immunoreactive for AM, but the in-
tensity was lower than that for the other cell types examined.
At the same stage, the visceral yolk sac, especially the vac-
uolated andmicrovillous border of the endodermal cells,was
immunostained for AM. By nonradioactive in situ hybrid-
ization showing a blue/black precipitate, AM and AM-R
mRNA were also localized to several cell types of the de-
veloping placenta, especially the giant trophoblastic cells
(Fig. 3, D–H).
Cardiovascular system. On day 8, most of the cells of the
developing mouse embryo were not stained, with the ex-
ception of the walls of the common atrial and ventricular
chambers of the primitive heart, which were slightly immu-
noreactive for AM. In the E9 embryo, the cardiac tube was
markedly immunostained with the antibodies against AM
(Fig. 4A) and also expressed the receptor mRNA. The de-
veloping heart was the organ that showed higher levels of
immunoreactivity throughout all stages of the mouse devel-
opment. The myocytes of both atrial and ventricular walls,
including the elaborate trabeculae formed around E10 in the
ventricular chamber, were strongly stained for both AM and
AMmRNA (Fig. 4, B–D). The differentiating smooth muscle
fibers found in the large arteries starting on E11 were
strongly immunoreactive for AM (data not shown).
Nervous system. The neural tube, which was negative for AM
during the preorganogenetic period (Fig. 1A), showed a de-
tectable level of AM-like material by day 10. In this stage, the
maturing cells of the ventral horn of the spinal cord showed
AM-like immunoreactivity (Fig. 4E). As development con-
tinued, both the maturing postmitotic neural cells of the
mantle layer and the neuropil of the marginal layer stained
for AM in E11 embryos. On E12 and the following days, the
difference between differentiated stained and less differen-
tiated unstained areas of the central nervous system was
more clear (Fig. 4F). From E12 on, specific groups of neurons
positive for AM could be seen in the central nervous system,
for example in the mantle layer of the spinal cord (Fig. 4F).
mRNA for AM and for its receptor was shown in these
neurons by in situ hybridization techniques (Fig. 4, G andH).
Neural crest-derived dorsal root ganglia and their segmental
nerve trunks became increasingly immunostained from
E11-12 on (Fig. 4, I–K). In the earlier stages (Fig. 4I) only the
trunks, but not neural cell bodies, were detectable with the
anti-AM antibodies, whereas in E14 embryos, both neurons
and nerve trunks were strongly stained (Fig. 4K). Through-
out the rest of the development, the pattern of staining that
was first seen in the nervous system on E12 remained, i.e.AM
TABLE 1. Tissue distribution of immunohistochemically detectable adrenomedullin in mouse organogenesis
Tissue Localization E8 E9 E10 E11 E12 E13 E14 E15 E16
Heart 1 2 3 3 3 3 3 3 3
Arterial vasculature 1 2 2 2 2 2 2
Central nervous system Brain 0 0 1 1 1 1 1 1 2
Pituitary 1 ND ND 1 1 1
Choroid plexus 0/1 2 2 2 2 2 2
Peripheral nervous system Spinal cord 0 0 1 1 1 2 2 2 2
Dorsal root ganglia 0 0/1 1 2 2/3 3 3
Eye Retina 0 0 0 0/1a 0/1a
Ear Choclear epithelium 0 1 1 1 1/2 2
Skeletal structures Skeletal muscle 0 1 2 2 2 2
Precartilaginous blastema 0
Perichondrium 0 0 0 0/1 0 0
Chondrocytes 0 1 2 2 2 2
Hypertrophic cartilage 3 2 2
Osteoblasts 2 2 3
Skin 1 2 2 2 2 2
Whisker follicles 1 2 2 2
Intestine Epithelium 1 1 1 1 2
Muscle fibers 1 2 2 2 2
Liver Hepatocytes 0 0 0 1 1 1
Megakaryocytes 1 1 1 1 1 1
Thymus Cortex ND 0 0 0
Medulla ND 0 1 1
Lung Epithelial cells 0 1 1 1 1b/0c 1b/1c 0b/2c
Mesenchyma 0/1 0 1 1 1 1 1
Airway smooth muscle cells 0/1 1 1
Kidney Metanephric duct derivatives 0 2 2 2 2
Forming tubules 0 0 0 0 1
Glomeruli 0 0 0/1d 1d 1d
Adrenal gland 1 2 2 2 2
Staining intensity is ranked from 0 (no staining) to 3 (very intense staining). ND, not determined.
a Outer neuroblastic layer.
b Prospective respiratory system.
c Prospective bronchial system.
d Glomerular capillary and mesangial tufts.
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was localized to the neuropil, individual or grouped neurons
within the central nervous system, and dorsal root ganglia.
A certain segmental progression in the degree of staining of
dorsal root ganglia could also be detected within a given
stage. Slight immunoreactivity was observed in the Rathke’s
pouch on E11 and in the forming adenohypophysis in later
stages of embryogenesis. Choroid plexi were also strongly
immunostained for AM throughout development. In the eye,
a discrete immunocytochemical signal was detected in the
outer neuroblastic layer of the retina on E14-15. In situ hy-
bridization showed that the mRNA for AM was present in
the same cells. The lens epithelium and the lens fibers were
stained with the antibodies against AM and, more strongly,
against PAMP (data not shown).
Skeletal and integumentary tissues. The presence of AM-im-
munoreactive material was observed at low levels in a dif-
fuse pattern on groups of mesenchymal cells from E9 on. The
mRNA forAMwas present in the same cells at this stage. The
expression of AM by the mesenchymal cells seems to follow
precise patterns of spacio-temporal distribution, as the de-
gree of staining of this tissue varied from one region to the
other and during development. In the E12-13 stage, when the
differentiation of the cartilaginous skeleton proceeds from
condensed mesenchyma/precartilage toward more mature
chondrocytic cells, AM-like material started to be expressed.
Precondensing mesenchymal cells were immunocytochem-
ically negative for AM (Fig. 4I). Maturing cartilage cells were
increasingly positive from E13 on (Fig. 4J), and hypertrophic
cartilage cells found from E15 were also highly stained (Fig.
4K). In situ hybridization showed that AM and AM-R
mRNAs were clearly present in maturing chondrocytes (Fig.
4, G and H). Osteoblasts of the developing bone in the later
stages of development were strongly immunoreactive for
AM. During tooth development, AM-like expression could
be observed on E15-16 in the condensing mesenchyme and
the columnar cells of the inner layer of the enamel epithelium
as well as in the underlying forming bone (Fig. 4L). After
differentiation, the striated muscle cells were also immuno-
reactive for AM. This was particularly evident between E12
and E14, when the tongue elongated and increased in vol-
ume, and the striated muscle fibers differentiated from the
myotubes (Fig. 1B). AM-like expression could be observed in
the outer layer of the early skin, the periderm, from the E10
stage andwas remarkably strong in the epidermal cells of the
more differentiated skin on day 14 and throughout the de-
velopmental stages that followed (Fig. 4F). AM mRNA and
the mRNA for the receptor could also be found by in situ
hybridization (Fig. 4, G andH). The cells that form the cortex
of the hair follicles were immunostained, whereas the mes-
enchyma that will form the papilla was negative (data not
shown).
Embryonic internal organs. Apart from the strong immuno-
staining found in the heart throughout development, other
internal organs expressed AM in the mouse embryo. In the
gut, development progressed in a proximal to distal direc-
tion, so that at one time point different segments of the gut
were at various stages of maturation. Initially, when the
lumen of the gut was small and was lined by a pseudostrati-
fied columnar epithelium, noAM staining could be observed
(Fig. 5A). In E13 embryos, a slight apical immunostaining
was present in the epithelial cells that formed the inner lining
of the midgut loops. As the gut matured, the peripheral
mesenchyme differentiated toward smooth muscle, whereas
the subepithelial mesenchymal tissue originated the lamina
propria, muscularismucosa, and submucosa. Prominent AM
expression was found on E13 in the mesenchymal cells that
will form the gut muscle layer. From E14 on, the presence of
AM in the epithelium increased. On E16, the more differen-
tiated simple columnar intestinal epithelium showed a
marked expression of AM locatedmainly in the apical region
of the enterocytes (Fig. 5B). On days 11–12, bilobed
megakaryocytes expressing AMwere particularly detectable
in the developing liver (data not shown). Although the pan-
FIG. 2. Expression of AM and its receptor in different regions of the
ratE16 embryo. Southern blot afterRT-PCR forAM (A) andAM-R (B).
C, Western blot using an antibody specific for AM (no. 2343). The
bands of higher mol wt may correspond to unprocessed precursor.
Absorption control was carried out for all tissues shown, but only one
representative lane is included.
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creatic primordia were initially negative for AM, on E14 a
number of cells in the developing pancreatic ducts became
immunoreactive for AM (Fig. 4D). The primordia of the
endocrine islets that could be seen on E14 budding off the
ductswere also intensely positive for AM (Fig. 4D). On E10.5,
when the early lung bud was already formed, no expression
was seen in the airway epithelium, and very little expression
was found in the mesenchyme that surrounds it (Fig. 4E). On
E11-12, the epithelium of the primordia of the bronchial tree
showed increasing staining. Mesenchymal expression of AM
in the lung was also increasingly present during these stages
and was particularly notable in E13-14 embryos (Fig. 4F). In
the lung of these embryos, the cells surrounding the devel-
oping bronchi that will differentiate into smoothmuscle cells
stained particularly strongly. Smooth muscle fibers of the
forming arteries also expressed high levels of AM-immuno-
reactivematerial at this stage. Byday 14, differentiation of the
tubular epithelial system into the prospective bronchial sys-
tem (central) and the prospective respiratory system (pe-
ripheral) had started. In E14-15 embryos. AM immunostain-
ing was present in the latter epithelia and absent in the
former. The pattern of staining reversed in later stages. In
E15-16 embryos, a very clear staining was found in the ep-
ithelial lining of developing bronchi; the smooth muscle and
the cartilage plates and rings of the bronchi and trachea were
also stained (Fig. 5H).During the formation of the kidney, the
first AM-expressing cells were found on E13-14 in the epi-
thelium of themetanephric duct and later in themetanephric
collecting tubules, but not in the mesenchyma, from which
primitive glomeruli forms (Fig. 5, I and J). Slight AM im-
munoreactivity was found in the epithelium of the devel-
oping nephrons at the late S-shape body stage and in the final
FIG. 3. Expression of AM and AM-R in
the mouse primitive placenta on E9. A,
Immunocytochemical detection of AM.
B, Detail of giant trophoblastic cells im-
munostained for AM. C, Absorption
control. D, Nonradioactive in situ hy-
bridization for AMmRNA in the mouse
placenta. E, Detail of the giant tropho-
blastic cells. F, Control using a sense
probe. G, In situ hybridization for
AM-R. H, Sense control. Magnification:
A, D, G, and H, 340; B, C, E, and F,
3200.
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FIG. 4. Expression of AM and its receptor in several mouse tissues. Unless otherwise stated, figures show AM immunocytochemical detection.
A, E9. Cardiac tube (arrow) and some mesenchymal cells are positive. B, E11. Atrium and ventricle are positive, whereas other organs are not
stained. C, E11. Detail of heart. Cardiomyocytes but not endocardial cells are positive. D, E11. In situ hybridization for AM mRNA in a region
similar to that shown inC. E, E10.Neural tube and related structures. Note themarginal layer of neural tube showing positive staining (arrows).
F, G, and H, Longitudinal sections of the forming spinal cord and related structures. Note that skin, spinal cord neurons, dorsal root ganglia,
and chondrocytes at vertebrae primordia express AM and its receptor. F, E12. G, E15. In situ hybridization for AM mRNA. H, E15. In situ
hybridization for AM-R mRNA. I–K, Expression of AM during maturation of dorsal root ganglia and cartilage. I, E11. J, E12. K, E14. L, E15.
Tooth primordium showing positive enamel epithelium and underlying forming bone. Magnification: A, B, E, F, G, and H, 340; C, D, K, and
L, 3100; J, 3200; I, 3300.
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FIG. 5. Expression of AM in several internal organs of the developing mouse. Unless otherwise stated, figures show AM immunocytochemical
detection. A–D, Digestive system. A, E13 gut. See differentiating smooth muscle immunostained for AM. B, E16 gut. C, E16 gut immunostained
for PAMP. D, E16 pancreas. Note positive forming islets budding off the ducts (arrows). E–H, Respiratory tract. E, E11 lung primordium. F,
E15 lung. Note positivemesenchymal staining. G, E16 lung. The epithelium of the airways is stained. H, E15 trachea. Epithelium, chondrocytes,
and smooth muscle are immunostained. I–L, Kidney and adrenals. I, E12 kidney primordium. J, E14 kidney. Note that only some ducts (those
derived from metanephric duct) are stained. K, E15 adrenal gland. L, E18. In situ hybridization to localize AM mRNA in the kidney. Only a
subpopulation of ducts express AMmRNA. Note medullar and cortical staining in adrenal gland. Striatedmuscle and chondrocytes also express
AM mRNA. Magnification: L, 340; B, C, E, G, H, I, J, and K, 3100; A, D, and F, 3200.
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stages of development in the capillary and mesangial cell
tufts of the developing glomeruli. The primordia of the ad-
renal glands expressed AM-immunoreactive material from
E12-13 (Fig. 5K). Later in development, immunoreactivity in
both the medulla and cortex of the adrenals could be found.
ThemRNA for AM followed the same pattern of distribution
at this stage (Fig. 5L).
Expression of PAMP in mouse development
The expression of the AM gene-related peptide PAMP in
the developing mouse was also studied. The pattern of ap-
pearance anddistribution of PAMPwas similar to that ofAM
(Figs. 1, C and D, and 5C). Nevertheless, the levels of im-
munocytochemical signal for PAMP were lower than those
for AM.
AM and PAMP expression in the developing rat
The distribution of AM and PAMP immunoreactivity in
the rat embryo was parallel to what we have described in the
mouse when equivalent stages were compared (some rep-
resentative examples can be found in Figs. 1, E and F, and 6).
The pattern of appearance and distribution of AM immu-
noreactivity in the rat was very similar to that in the mouse,
but occurred 1.5–2 days latter in development. Nevertheless,
some differences were found between the two species. In the
embryonic rat, endothelial cells expressed AM earlier and in
a broader pattern than those in the mouse. AM-immunore-
active endothelial cells could be found as early as the E10
stage in the rat embryo and were also found in some very
small vessels, such as those in developing glomeruli, on
E16-17. The smaller blood vessels were less frequently
FIG. 6. Representative examples of ex-
pression of AM in rat development. Un-
less otherwise stated, figures show AM
immunocytochemical detection. A, E11
giant trophoblastic cells. B, E15. In situ
hybridization for AM in the heart. C,
E18. In situ hybridization for AM re-
ceptor in mature and hyperplastic car-
tilage of the vertebrae. D, E16 stomach.
Note that both epithelium and develop-
ing muscle layer are stained. E, E16
pancreas. Both endocrine and ductal
cells are stained. F, E16 lung. Note pos-
itive staining on the forming smooth
muscle surrounding the airways. G,
E16 kidney. Metanephric duct and de-
rived ducts are positively stained. Im-
munostained tissue of the adrenal
gland can be seen in the left upper cor-
ner. H, E18. In situ hybridization for
AM mRNA in the kidney. Apart from
the ducts, some cells of the differenti-
ating glomeruli express AM. Magnifi-
cation: B and H,340; C and F,3100; A,
D, E, and G, 3200.
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stained for AM in the developingmouse embryo. A clear AM
staining for differentiated hepatocytes was found in the E17
rat embryo, which was less apparent in the equivalent stage
of mouse development. In general, the later stages of devel-
opment of rat embryos showed higher levels of AM immu-
noreactivity than the equivalent stages in the mouse. In situ
hybridization for mRNA as well as for AM-R showed a
parallel anatomical distribution. Our Western blot results
(Fig. 2C) showed the presence of immunoreactive ad-
renomedullin in several organs of the E16 and E18 rat em-
bryo. RT-PCR of isolated total mRNA also confirmed the
presence of AM and AM-Rmessage in the same stages of the
rat embryo (Fig. 2, A and B).
Discussion
The results of our study strongly indicate that AM, AM-R,
and PAMP are present in a large number of embryonic and
extraembryonic cells and tissues in developing mouse and
rat. Both the fetal and maternal tissues of the primitive pla-
centa express high levels of these molecules. In the embryo
proper, the onset of the increasing expression of AM-like
peptide and mRNA occurs in the early organogenetic period
in both species. Initially, it is restricted to limited regions of
the embryo, but progresses to encompass most of the tissues
and organs in the final stages of development. Our results
suggest that this regulatory peptide may have an important
function(s) in the complex biological processes taking place
in embryogenesis.
To strengthen the conclusions drawn from the analysis of
our immunocytochemical data concerning localization of
AM, we have studied the distribution of PAMP encoded in
the same precursor. The difference in intensity of immuno-
staining between AM and PAMP may reflect variations in
intracellular levels of both peptides, possibly as the result of
regulation of posttranslational processes. Alternatively,
these differences may be due to the characteristics of the two
antisera; in fact, solid phase RIA characterization studies (see
Materials and Methods) showed that the antiserum used to
detect PAMP (no. 2463) has lower titer than the one against
AM (no. 2343).Moreover, we performed in situ hybridization
studies using a specific probe to detect adrenomedullin
mRNA. The three different approaches (localization of AM,
PAMP, and their mRNA) show similar, if not identical, pat-
terns of distribution. A further verification of our data comes
from the simultaneous study of embryos of two species that
also show a very analogous spatio-temporal pattern of AM
expression. Finally, Western blot and RT-PCR analysis of
total embryos and dissected late embryonic tissues were
performed. Our biochemical results also show that both ad-
renomedullin and its receptor are present in different organs
during development.
In general, the organs that express AM during murine
development correspond to those described for adults, de-
termined by RIA, Northern blot, and immunocytochemistry
(10, 11, 23), with heart and adrenals showing higher levels of
expression in both cases. Nevertheless, comparison of the
distribution of immunocytochemical staining suggests that
the relative AM expression in embryonic tissues in late or-
ganogenesis is even broader than that in adults.
The gene that codes for a membrane receptor protein spe-
cific for AM has recently been cloned from rat lung (16). Our
results show a widespread distribution of the receptor in
many tissues and organs of the developing mouse and rat.
To date, the cellular distribution of this receptor has not been
reported, with the exception of rat pancreas and lung (23, 24).
The fact that the distribution of the AM receptor in most
organs colocalizes with the ligand supports the hypothesis
that AM may act locally in a short range autocrine or para-
crine mode. Several other growth factors, such as platelet-
derived growth factor (PDGF) or the several transforming
growth factors-b (TGFbs), have been proposed to work in an
autocrine/paracrine manner on the basis of a close juxtapo-
sition, or even identity, of the cells expressing the receptors
and the cells that secrete these factors (1, 4).
The formation of organs during embryogenesis is highly
dependent on the sequential and time-regulated expression
of a number of growth factors (26). The pattern of distribu-
tion of AM-like immunoreactivity and its mRNA during
murine development is very similar to that of other well
established peptide growth factors. The distribution of AM
immunoreactivity shown in our study is very similar to that
reported for the TGFb isoforms 1, 2, and 3 in the E12-18.5
mouse embryos (2, 27), suggesting that AM and the TGFbs
could be involved in analogous functions. AM distribution
also shows some coincident locations with other active pep-
tides such as PDGF, the fibroblast growth factors, insulin-like
growth factors I and II, and the recently discovered car-
diotropin, a member of the leukemia inhibitory factor/in-
terleukin-6 family. On a comparative basis with the data
available on the above-mentioned growth factors, AM seems
to be the peptide that is expressed in a larger variety of cells
and tissues throughout development, which suggests that
this peptide is an important requirement for development to
proceed in most organs.
An interesting finding is that AM is intensely expressed in
tissues and organs where strong mesenchymal-epithelial in-
teractions take place, such as kidney, lung, tooth primordia,
and hair follicles. The expression of AM in these structures
is tightly regulated and restricted to particular structures in
a given developmental stage. In the kidney, for example, AM
is initially expressed only in the ureteric bud-derived met-
anephric ducts. Later in development, the differentiating
nephron tubules and the glomeruli tufts begin to express
AM.Other growth factors, such as insulin-like growth factors
I and II, TGFb1 and -2, and PDGF are also expressed in the
developing kidney in a very specific spatial and temporal
pattern (8).
In adult mammals, AM has been shown to have multiple
and diverse functions. A broad spectrum of functions, such
as in vivo and in vitro regulation of embryonic cell prolifer-
ation, differentiation, and migration, is also a common fea-
ture for other thoroughly studied growth factors (for a re-
view, see Ref. 26). Our results on the localization of AM and
its receptor together with the available data on the diverse
functions of AM have lead us to formulate the hypothesis
that AM could be involved in the regulation of mammalian
morphogenesis, possibly through the control of cell prolif-
eration, differentiation, and migration.
Several reports have shown that AM acts as a true growth
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factor in several normal and malignant tissues. The potent
mitogenic effect of AM on embryonic mouse fibroblasts has
been reported recently (32). AM also stimulates growth in
tumor cell lines via an autocrine loop (25) and promotes cell
cycle progression from the G0 to the G1 phase and the ex-
pression of c-fosmRNA in vascular smooth muscle cells (20).
These reports coincide by showing a cAMP-dependent signal
of transduction pathway effecting growth for AM. Interest-
ingly, AM seems to act also as a suppressor of mitogenesis
in cultured rat mesangial cells and vascular smooth muscle
(5). This duality of regulatory functions could be due to the
participation of different protein kinase isoforms in the cel-
lular response to AM (12).
A functional relationship between the expression of AM
and differentiation can be deduced by the anatomical dis-
tribution of AM immunoreactivity and mRNA. In many em-
bryonic organs, AM expression seems to correlate with the
onset and progression of the differentiation process. For ex-
ample, in the formation of the cartilaginous templates that
precede bone, AM and AM-R seem to be expressed in the
more mature cell types in the chondrocyte lineage, including
the hypertrophic cells, whereas the condensing mesenchy-
mal cells that are present in the previous stages express very
low, if any, levels of the peptide and its receptor. The ex-
pression of growth factors in the formation of cartilage has
been the object of a number of studies (7). Interestingly, a
relationship between cAMP and terminal differentiation and
calcification of cultured chondrocytes has been clearly es-
tablished (13), which could support the involvement of AM
in the regulation of this process through its cAMP-dependent
signal transduction system. Various other active factors that
affect chondrocyte differentiation also increase the cAMP
concentration in chondrocytes (17). The localization of AM,
its mRNA, and the mRNA of its receptor to the growing
skeletal structures and the fact that AM elicits its biological
actions via the elevation of cAMP levels suggest an involve-
ment of AM in embryonic chondrocyte maturation. Further
investigation is required into the proper in vitro and in vivo
models to clarify the exact role of AM in chondro- and os-
teogenesis. Another example in which the expression of AM
seems to be associated with the degree of differentiation is
neural tissue. Although in the early neural tube, neither
immunocytochemical signal of AM nor mRNA of the ligand
or the receptor is present, as development proceeds, AM
starts to be expressed in many of the more mature and
differentiated regions of the central nervous system. The
expression of AM in the dorsal root ganglia neurons is also
increased in the later stages of development, especially from
themomentwhenmost of the dorsal root ganglia neurons are
probably formed (21).
Our immunocytochemical results as well as the data on
localization of themRNAof AMand its receptor consistently
show that trophoblastic cells, in particular the giant tropho-
blastic cells, express AM andAM-R at high levels. A possible
autocrine or paracrine loop that could regulate the physiol-
ogy of this cell type is proposed. Murine giant trophoblast
cells as well as their human counterparts share in vivo and in
vitro invasive properties with malignant cells (33). The AM
regulatory role on these cells could be similar to that of TGFb,
which is known to be produced by trophoblast cells and
seems to be involved in the regulation of trophoblast inva-
siveness via the induction of tissue inhibitor of metallopro-
teases and by decreasing collagenase IV activity (6). Inva-
siveness by trophoblastic cells is also regulated by leukemia
inhibitory factor and epidermal growth factor via the stim-
ulation of matrix metalloproteases and other proteinases (9).
In summary, our study has shown a widespread expres-
sion of the recently discovered multifunctional peptide AM,
its receptor, and its gene-related peptide PAMP throughout
the organogenetic stages ofmouse and rat embryos. Based on
the sites of expression and by analogy with other multifunc-
tional growth factors for which functional studies have been
performed, we propose that the AM regulatory system may
play an important role in a variety of key processes in em-
bryonic development, namely in the control of growth, dif-
ferentiation, and invasion. Further functional evaluation, on
the basis of our distributional study, will clarify the validity
of our hypothesis.
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